MTX tolerant | MTX intolerant | p | |
---|---|---|---|
Female Gender | 74/106 | 67/90 | 0. 525 |
Age | 9,67 ± 4,42 | 10,83 ± 3,89 | 0. 055 |
Age at diagnosis | 5,53 ± 4,09 | 5,13 ± 4,04 | 0. 495 |
Disease duration | 4,14 ± 3,54 | 5,70 ± 3,78 | 0. 003* |
Duration of MTX treatment | 1,83 ± 2,33 | 2,45 ± 2,32 | 0. 064 |
MTX dose/m2 BSA | 12,29 ± 2,08 | 11,63 ± 2,00 | 0. 026 |
s.c. dosing | 47/106 | 40/90 | 1. 000 |
Folic acid supplementation | 103/106 | 81/90 | 0. 069 |
Elevated LFT | 18/106 | 22/90 | 0. 217 |
Treatment with TNFA | 47/106 | 33/90 | 0. 309 |
Treatment with NSAID | 37/106 | 31/90 | 1. 000 |